Victor Appay, PhD, explains how long-term ART slows immune aging, boosting HIV viral suppression and paving the way for ...

The rate of HIV infection continues to climb globally. Around 40 million people live with HIV-1, the most common HIV strain. While symptoms can now be better managed with lifelong treatment, there is ...

The efficiency of HIV-1 replication hinges on the dynamic interplay between viral RNA and an array of viral and host proteins. At the core of this process is the dual role of the unspliced viral RNA, ...

In an important discovery, researchers from Florida Atlantic University's Charles E. Schmidt College of Medicine have identified a never-before-seen mechanism that enables the human immunodeficiency ...

The tiny shell protecting the HIV virus resembles a slightly rounded ice cream cone, but there is nothing sweet about it.

IMPAACT 2017 (MOCHA) week 96 results show long-acting Cabenuva (cabotegravir + rilpivirine) effectively maintained viral suppression in 94.4% of adolescents aged 12 to <18 years Additional paediatric ...

A team of scientists at the Helmholtz Institute for RNA-based Infection Research (HIRI) in Würzburg and the University of Regensburg has unveiled insights into how HIV-1, the virus responsible for ...

ViiV Healthcare’s long-acting Cabenuva for HIV demonstrates superior efficacy compared to daily oral therapy for people with adherence challenges: London, UK Friday, February 20 ...